Infinimmune is a technology company.
Infinimmune has raised $12.0M across 1 funding round.
Infinimmune has raised $12.0M in total across 1 funding round.
Infinimmune has raised $12.0M in total across 1 funding round.
Infinimmune's investors include DBL Partners, Future Shape, GE Ventures, Khosla Ventures, Morpheus Ventures, Marc van den Berg, Paladin Capital Group, Piva Capital, Playground Global, Trucks Venture Capital, Bradley Horowitz.
Infinimmune is a biotechnology company developing next-generation antibody therapeutics derived entirely from human immune systems, targeting autoimmune diseases and cancer.[1][2] Using its proprietary Anthrobody™ platform powered by Complete Human™ immunosequencing technology, the company mines human antibody repertoires to create complete human antibodies—including nanobodies, fusion proteins, and novel constant regions—that offer superior safety, efficacy, and specificity compared to animal- or AI-generated alternatives.[2][3][6] These therapeutics address unmet needs in treating complex human diseases by leveraging antibodies pre-selected *in vivo* for function and low immunogenicity.[2][4]
Founded in 2022 and headquartered in San Francisco (with operations noted in Alameda), Infinimmune has raised $12M in seed VC funding from investors including Pear VC, Playground Global, and Civilization Ventures, achieving early preclinical momentum with a pipeline featuring validated interleukin inhibitors, immuno-oncology candidates, and undisclosed targets.[1][3][4] Recent advancements include the launch of GLIMPSE-1, an AI protein language model trained on human antibody data, enabling scalable engineering of high-potency candidates with 95% less data than competitors while matching top performance.[4]
Infinimmune was founded in 2022 by a small team of five technologists with roots at 10x Genomics, who identified gaps in single-cell antibody discovery technologies that missed diverse human antibodies.[1][4] Wyatt McDonnell, Co-Founder and CEO, leads the effort, emphasizing learning directly from the human adaptive immune system to engineer superior antibodies for autoimmune and beyond.[4][5] The idea emerged from observing pharmaceutical struggles with under-adopted single-cell tools and inefficient methods like hybridomas, prompting the development of a high-throughput platform screening millions of antibody sequences against hundreds of targets.[4]
Early traction built rapidly: the team created Complete Human™ technology to capture *in vivo*-selected antibodies, followed by the Anthrobody™ platform and GLIMPSE-1 AI model.[2][3][4] A pivotal moment came in September 2024 with the appointment of Dr. Tim Sullivan as Chief Business Officer to scale partnerships, alongside plans for Series A funding, clinical entries, and global pharma deals.[1]
Infinimmune stands out in antibody drug discovery through its exclusive focus on complete human antibodies—full-chain molecules produced by human immune systems, unlike transgenic animal, display library, or synthetic approaches.[2][6] Key strengths include:
These enable faster, safer translation to clinic, filling gaps in public datasets for autoreactive antibodies.[4][6]
Infinimmune rides the convergence of AI-driven protein design and human-centric biotech, capitalizing on advances in single-cell sequencing and immunosequencing to unlock the human antibody repertoire's untapped potential.[2][4] Timing is ideal amid surging demand for safer biologics—over one-third of naive B-cell antibodies are autoreactive goldmines for autoimmune therapies, yet traditional tools fail to capture them efficiently.[4][6] Market forces like rising autoimmune/cancer prevalence, AI's rise in drug discovery (e.g., via models like Sapiens), and pharma's push for de-risked assets favor Infinimmune's approach, which bypasses immunogenicity pitfalls of non-human antibodies.[1][4][6]
The company influences the ecosystem by pioneering human-derived nanobodies and fusions, challenging dominant players reliant on animal models or algorithms, and enabling broader access to *in vivo*-optimized therapeutics through partnerships and open innovation signals like GLIMPSE-1.[2][4]
Infinimmune is poised for Series A funding and first clinical trials in 2025, with GLIMPSE-1 engineering lead assets into Phase 1/2 for autoimmune diseases and immuno-oncology, alongside global pharma partnerships.[1][4] Trends like multimodal AI-biotech integration, expanding single-cell data troves, and precision medicine will amplify its edge, potentially evolving it into a pipeline powerhouse with blockbuster human antibodies. As the first to systematically exploit complete human repertoires, Infinimmune redefines antibody discovery—turning the body's daily trials into tomorrow's cures.[2]
Infinimmune has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $12.0M Seed | DBL Partners, Future Shape, GE Ventures, Khosla Ventures, Morpheus Ventures, Marc van den Berg, Paladin Capital Group, Piva Capital, Playground Global, Trucks Venture Capital, Bradley Horowitz |